TipRanks
Go Ultimate55% OFF

Corcept Therapeutics (HTD) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

HTD Analyst Ratings

Strong Buy
4Ratings
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Corcept Therapeutics in the past 3 months

HTD Stock 12 Month Forecast

EUR 146.62▲(102.46% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is EUR 146.62 with a high forecast of EUR 147.74 and a low forecast of EUR 144.16. The average price target represents a 102.46% change from the last price of EUR 72.42.
Highest Price TargetEUR 147.74Average Price TargetEUR 146.62Lowest Price TargetEUR 144.16

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:HTD
Price TargetFollowArticle
H.C. WainwrightEUR 147.74buy104.01%UpsideReiterated11/02/26
Canaccord GenuityEUR 144.16buy99.06%UpsideReiterated10/27/26
Piper SandlerEUR 147.74buy104.01%UpsideReiterated10/27/26
Truist FinancialEUR 44.77→EUR 146.85buy102.77%UpsideInitiated08/18/26
Wolfe ResearchEUR 44.77sell-38.18%DownsideReiterated07/29/26
UBSEUR 64.47buy-10.98%DownsideUpgraded05/13/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Edward Nash
Edward NashCanaccord Genuity
Success Rate23/35 ratings generated profit
66%
Average Return
+13.67%

Copying Edward Nash's trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +13.67% per trade.

1 Year
David Amsellem
David AmsellemPiper Sandler
Success Rate22/29 ratings generated profit
76%
Average Return
+49.11%

Copying David Amsellem's trades and holding each position for 1 Year would result in 75.86% of your transactions generating a profit, with an average return of +49.11% per trade.

2 Years
David Amsellem
David AmsellemPiper Sandler
Success Rate26/29 ratings generated profit
90%
Average Return
+78.58%

Copying David Amsellem's trades and holding each position for 2 Years would result in 89.66% of your transactions generating a profit, with an average return of +78.58% per trade.

HTD Analyst Recommendation Trends

010203040Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
Monthly rating counts for HTD
RatingJun 26Jul 26Aug 26Sep 26Oct 26
Strong Buy30023
Buy1010985
Hold00000
Sell22200
Strong Sell00000
total151211108

In the current month, HTD has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HTD average Analyst price target in the past 3 months is 146.62.

HTD Financial Forecast

EUR -2EUR -1.25EUR -0.5EUR 0.25EUR 1Q4 2025Q2 2026Q3 2026
HighEUR 0.92
ConsensusEUR 0.71
LowEUR 0.55

HTD Earnings Forecast

Next quarter’s earnings estimate for HTD is EUR 0.71 with a range of EUR 0.55 to EUR 0.92. The previous quarter’s EPS was EUR 0.32. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.

EUR 147.7MEUR 189.1MEUR 230.5MEUR 272MEUR 313.4MQ4 2025Q2 2026Q3 2026
HighEUR 313M
ConsensusEUR 301M
LowEUR 295M

HTD Sales Forecast

Next quarter’s sales forecast for HTD is EUR 301.18M with a range of EUR 295.02M to EUR 313.39M. The previous quarter’s sales results were EUR 229.35M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.

HTD Stock Forecast FAQ

What is DE:HTD’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics’s 12-month average price target is €146.62.
What is DE:HTD’s upside potential, based on the analysts’ average price target?
Corcept Therapeutics has 102.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Corcept Therapeutics a Buy, Sell or Hold?
Corcept Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Corcept Therapeutics’s share price target?
The average share price target for Corcept Therapeutics is €146.62. This is based on 4 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €147.74, and the lowest forecast is €144.16. The average share price target represents a 102.46% increase from the current price of €72.42.
What do analysts say about Corcept Therapeutics?
Corcept Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of Corcept Therapeutics?
To buy shares of DE:HTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.